Inogen (NASDAQ:INGN) Shares Cross Above 50-Day Moving Average – Here’s Why

Shares of Inogen, Inc (NASDAQ:INGN) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $8.33 and traded as high as $8.66. Inogen shares last traded at $8.53, with a volume of 134,299 shares trading hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Inogen in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $11.00.

Inogen Stock Down 1.5%

The stock has a market cap of $230.65 million, a price-to-earnings ratio of -8.05 and a beta of 1.80. The company has a 50 day simple moving average of $8.33 and a 200 day simple moving average of $7.31.

Inogen (NASDAQ:INGN) last issued its earnings results on Thursday, August 7th. The medical technology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07. The firm had revenue of $92.28 million during the quarter, compared to the consensus estimate of $90.40 million. Inogen had a negative return on equity of 13.77% and a negative net margin of 7.58%. Inogen has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts predict that Inogen, Inc will post -1.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Kent Lake PR LLC increased its stake in shares of Inogen by 5.7% in the second quarter. Kent Lake PR LLC now owns 1,061,294 shares of the medical technology company’s stock valued at $7,461,000 after buying an additional 57,700 shares during the period. Acadian Asset Management LLC increased its stake in shares of Inogen by 35.7% in the first quarter. Acadian Asset Management LLC now owns 1,028,322 shares of the medical technology company’s stock valued at $7,325,000 after buying an additional 270,453 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Inogen by 0.8% in the second quarter. Ameriprise Financial Inc. now owns 881,100 shares of the medical technology company’s stock valued at $6,194,000 after buying an additional 6,573 shares during the period. Armistice Capital LLC acquired a new position in shares of Inogen in the second quarter valued at approximately $4,668,000. Finally, Prudential Financial Inc. increased its stake in shares of Inogen by 7.9% in the second quarter. Prudential Financial Inc. now owns 647,188 shares of the medical technology company’s stock valued at $4,550,000 after buying an additional 47,267 shares during the period. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.